Document:

<PAGE>

                                  EXHIBIT 10.7

       Fourth Amendment Dated March 18, 1993 to License Agreement Between
         the Company and the Massachusetts Institute of Technology dated
                         December 14, 1987, as Amended

<PAGE>

                                FOURTH AMENDMENT

         This Amendment with Effective Date of March 19, 1993 is to the License
Agreement between M.I.T. and Matritech, Inc. with the Effective Date of December
14, 1989.

         The parties thereto hereby agree that the time specified for completion
of the milestone identified in paragraph 3.2(c) be extended until June 30, 1994.

Agreed to for:

MATRITECH, INC.                                      MASSACHUSETTS INSTITUTE
                                                     OF TECHNOLOGY

By /s/ Stephen D. Chubb                      By /s/ John T. Preston
-----------------------------------          ----------------------------------

Title  President and CEO                     Title Director Technology
-----------------------------------          ----------------------------------

Date March 18, 1993                          Date March 18, 1993
-----------------------------------          ----------------------------------<PAGE>

                                  EXHIBIT 10.8

       Fifth Amendment Dated April 14, 1994 to License Agreement Between
        the Company and the Massachusetts Institute of Technology Dated
                         December 14, 1987, as Amended

<PAGE>

                                 FIFTH AMENDMENT

         This Amendment with Effective Date of April 12, 1994 is to the license
Agreement between M.I.T. and Matritech, Inc. with the Effective date of December
14, 1987.

         The parties thereto hereby agree that the time specified for completion
of the milestone identified in paragraph 3.2(c) be extended until December 31,
1994.

Agreed to for:

MATRITECH, INC.                              MASSACHUSETTS INSTITUTE
                                             OF TECHNOLOGY

By /s/ Stephen D. Chubb                      By /s/ John T. Preston
-----------------------------------          -----------------------------------

Title Chairman and Chief
      Executive Officer                      Title Director/Tech.
-----------------------------------          -----------------------------------

Date April 14, 1994                          Date April 14, 1994
-----------------------------------          -----------------------------------<PAGE>

                                                                    EXHIBIT 10.9

                          SUPPLY AND PURCHASE AGREEMENT

                                     BETWEEN

                                 MATRITECH INC.

                                       AND

                               KONICA CORPORATION

<PAGE>

                          SUPPLY AND PURCHASE AGREEMENT

This Agreement, made and entered into as of this 17th day of November, 1994 by
and between MATRITECH INC., with its principal place of business at 763 Concord
Avenue, Cambridge MA 02138, U.S.A. ("MATRITECH"), and KONICA CORPORATION, with
its principal place of business at 26-2, Nishi-Shinjuku 1-chome, Shinjuku-ku,
Tokyo, Japan ("KONICA"),

                                WITNESSETH THAT:

WHEREAS:

(A)  MATRITECH is engaged in the manufacture and sale of certain kinds of
     urinary tract disorders test kit for the purpose of diagnosis, prognosis,
     monitoring or treatment of human disease including cancer and is willing to
     supply KONICA with such products; and

(B)  KONICA wishes to purchase from MATRITECH such products as mentioned above
     (A) for the marketing, distribution and servicing, subject to the terms and
     conditions contained hereinafter.

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, both parties agree as follows:

1.   DEFINITIONS

(a)  "PRODUCTS" as used herein means the test kit detecting the urinary tract
     disorders and/or diseases which consists of a microtiter plate based enzyme
     immunoassay, and quantifies NMP22 in urine of patients for the diagnosis,
     monitoring or prognosis of urinary tract disorders and/or diseases, and
     further includes 96 determinations per test kit; and All succeeding
     PRODUCTS and improved PRODUCTS, including but not limited to all improved
     test kit which consists of any kinds of immunoassay to quantify NMP22 in
     urine by other methods than the microtiter plate based method.

<PAGE>

                                      -2-

(b)  "TERRITORY" as used herein means Japan and other countries to be agreed
     upon between both parties.

(c)  "TRADEMARKS" as used herein means the trademarks which consist of a
     combination of i) PRODUCTS name [JAPANESE CHARACTERS] Matritech UNMP22
     [JAPANESE CHARACTERS] which means "KONICA Matritech UNMP22 TEST KIT", ii)
     MATRITECH's trademark "device and Matritech" and iii) KONICA's trademark
     "Konica". "TRADEMARKS" shall be more specified in the Exhibit A attached
     hereto.

(d)  "KOSEISHO" as used herein means the Ministry of Health and Welfare of
     Japan.

(e)  "KOSEISHO APPROVAL" as used herein means the approval and permits of
     KOSEISHO for the purpose that KONICA can import and market PRODUCTS into
     Japanese market and specifically does not include the approvals necessary
     for assignment of reimbursement points or compensation such as Social
     Insurance Medical Fee.

(f)  "SALES YEAR" as used herein means a one (1) year period starting with the
     procurement of KOSEISHO APPROVAL or any of anniversary dates thereof.

2.   SUPPLY AND PURCHASE

2.1  During the term of this Agreement, KONICA shall have the exclusive right
     for marketing, distribution and servicing of PRODUCTS in the TERRITORY in
     consideration of the non-refundable payment of the exclusivity fee pursuant
     to Section 2.5 below. MATRITECH agrees to supply PRODUCTS to KONICA and
     KONICA agrees exclusively to purchase PRODUCTS from MATRITECH for
     marketing, distribution and servicing in the TERRITORY, subject to the
     terms and conditions contained herein. KONICA agrees not to sell any other
     products than the test kits to quantify NMP22 in urine, which are
     competitive with PRODUCTS within the TERRITORY.

2.2  So long as KONICA fully performs its obligation hereunder within the
     TERRITORY, MATRITECH agrees that, during the term of this Agreement; i) it
     shall not appoint any entity other than KONICA to act as a distributor for
     the PRODUCTS in the TERRITORY, and ii) it shall not sell the PRODUCTS to
     the customers in the TERRITORY. MATRITECH shall prevent possible re-export
     of PRODUCTS into the TERRITORY by any MATRITECH's distributor outside the
     TERRITORY, but assumes no responsibility for any such re-export if such
     re-export is beyond MATRITECH's

<PAGE>

                                      -3-

     control. MATRITECH reserves the right to sell components of the PRODUCTS to
     other manufacturers within the TERRITORY; provided, however, that KONICA
     shall have the right of first refusal to purchase Anti-NMP22 monoclonal
     antibody ("ANTIBODY") from MATRITECH, and even if KONICA refuses to
     purchase ANTIBODY, MATRITECH shall guarantee that KONICA's exclusive right
     for the PRODUCTS as set forth in Section 2.1 shall not be infringed by any
     products which have the purpose of quantifying NMP22 in urine and are
     manufactured by other manufacturers purchasing such ANTIBODY.

2.3  KONICA hereby agrees not to sell, re-export, re-ship or otherwise engage in
     distributing or servicing PRODUCTS directly in or to areas outside the
     TERRITORY, without the prior written consent of MATRITECH.

2.4  MATRITECH shall establish and maintain, at its own expenses and
     responsibility, an adequate production capacity to enable to manufacture at
     least [REDACTED] kits of PRODUCTS per manufacturing lot for KONICA to
     fulfil KONICA's one (1) purchase order in accordance with this Agreement.

2.5  KONICA agrees to pay MATRITECH the non-refundable amount of US$ 225,000 as
     the exclusivity fee for marketing, distribution and servicing of PRODUCTS
     in the TERRITORY. Payment shall be made by telegraphic transfer to
     MATRITECH at the date of execution hereof.

3.   MINIMUM QUANTITY

3.1  KONICA shall purchase yearly the following minimum quantity of PRODUCTS
     ("MINIMUM QUANTITY") from MATRITECH, during the term of this Agreement:

     1st SALES YEAR:   [REDACTED] kits

     2nd SALES YEAR:   [REDACTED] kits

     3rd SALES YEAR:   To be mutually determined at 6 months prior to the end of
                       the preceding SALES YEAR.

     4th SALES YEAR:   To be mutually determined at 6 months prior to the end of
                       the preceding SALES YEAR.

     5th SALES YEAR:   To be mutually determined at 6 months prior to the end of
                       the preceding SALES YEAR.

<PAGE>

                                      -4-

     In the event that KONICA fails to meet the MINIMUM QUANTITY obligation in a
     given SALES YEAR, KONICA may forfeit, at the sole discretion of MATRITECH,
     its right to serve as exclusive distributor for the PRODUCTS.

3.2  For the purpose of the foregoing Section 3.1, PRODUCTS shall be credited to
     the MINIMUM QUANTITY for the relevant SALES YEAR, at the time when
     MATRITECH receives KONICA's purchase order which shall be placed in
     accordance with Section 4 below; provided, that such creditable purchase
     order shall be limited to those to be placed at least sixty (60) days prior
     to the end of relevant SALES YEAR and the quantity of PRODUCTS under the
     purchase order placed after the beginning of such sixty (60) day period
     shall be credited to the MINIMUM QUANTITY for the next SALES YEAR.

4.   ORDERING PROCEDURE

4.1  KONICA shall place a purchase order for PRODUCTS by sending to MATRITECH a
     written order based on KONICA's form.

4.2  With respect to each purchase order placed by KONICA, MATRITECH shall
     notify KONICA of whether MATRITECH accepts the purchase order or not,
     within five (5) MATRITECH working days after the receipt of the purchase
     order; provided, however, that the purchase order placed by KONICA shall be
     deemed to be accepted by MATRITECH in case no notice of acceptance or
     rejection is received by KONICA within such five (5) MATRITECH working day
     period. The individual sales contract ("SALES CONTRACT") hereunder shall
     become effective, if and as MATRITECH accepts the purchase order in
     accordance with above mentioned provision.

4.3  In case KONICA deems it necessary to revise the SALES CONTRACT, KONICA may
     make such revisions by the consent of MATRITECH.

4.4  The minimum order quantity of each purchase order placed by KONICA during
     the term of this Agreement shall be as follows:

     Before 1st SALES YEAR: [REDACTED] kits per order
     1st and 2nd SALES YEAR: [REDACTED] kits per order
     3rd and 4th SALES YEAR: [REDACTED] kits per order
     5th SALES YEAR and thereafter: To be negotiated

<PAGE>

                                      -5-

4.5  In case of discrepancy between SALES CONTRACT and this Agreement, this
     Agreement shall prevail.

5.   PRICE AND PAYMENT

5.1  The transfer price per kit of PRODUCTS shall be determined by both parties
     in accordance with the following chart, and shall be quoted on an Ex Works
     MATRITECH's warehouse in Cambridge basis:

--------------------------------------------------------------------------------
Social Insurance Medical Fee               Transfer Price per kit
--------------------------------------------------------------------------------
     [REDACTED] points or less                   US$[REDACTED] per point
--------------------------------------------------------------------------------
     [REDACTED] points to 350 points             US$[REDACTED]
--------------------------------------------------------------------------------
     [REDACTED] points or more                   US$[REDACTED] per point
--------------------------------------------------------------------------------

     MATRITECH shall promptly transfer KONICA with free of charge the formulas
     and other written informations as necessary and as required for
     manufacturing the urine sample stabilizer for PRODUCTS by KONLCA. Until
     February 1, 1995, MATRITECH shall supply KONICA with reasonable quantities
     of stabilizer and tubes as manufactured by MATRITECH at free of charge,
     upon request by KONICA.

5.2  The transfer price of PRODUCTS as set forth in Section 5.1 above shall be
     fixed for a period from the execution date hereof until the end of 2nd
     SALES YEAR. Following 2nd SALES YEAR, both parties shall determine with
     mutual consultation and agreement, the new transfer price of PRODUCTS
     applied in each SALES YEAR at least six (6) months prior to the beginning
     of such SALES YEAR, taking into consideration the changes in the production
     costs, market conditions in the TERRITORY and other factors; provided, that
     in case the new transfer price can not be determined at such time
     notwithstanding reasonable efforts of both parties, the transfer price of
     the preceding SALES YEAR shall be applied in the next SALES YEAR.

5.3  Notwithstanding the provisions of Sections 5.1 and 5.2 hereof, the transfer
     price of PRODUCTS shall be discounted at the rate of [REDACTED] percent
     [REDACTED] from the then current price for the entire next SALES YEAR, if
     KONICA purchased [REDACTED] kits or more of PRODUCTS from MATRITECH in the
     preceding SALES YEAR pursuant to Section 3.1.

<PAGE>

                                      -6-

5.4  For the purpose of payment, KONICA shall remit the amount of PRODUCTS by
     telegraphic transfer in U.S. dollars to MATRITECH not later than thirty
     (30) days after receiving MATRITECH's invoice of relevant PRODUCTS.

6.   DELIVERY

6.1  MATRITECH shall make timely shipment and delivery for PRODUCTS to KONICA
     within sixty (60) days after the date of relevant purchase order placed by
     KONICA. The delivery shall be made on an Ex Works MATRITECH's warehouse in
     Cambridge basis. MATRITECH shall exert its best efforts to deliver PRODUCTS
     manufactured in the same manufacturing lot to KONICA for each SALES
     CONTRACT.

6.2  Title to PRODUCTS shall pass from MATRITECH to KONICA at the point of time
     when the risk of loss for PRODUCTS shall pass from MATRITECH to KONICA in
     accordance with the provisions of the "Incoterms" as set forth in Section
     31.1.

6.3  MATRITECH shall, at its expenses, conduct and arrange necessary measures as
     required by MATRITECH and consented by KONICA, including but not limited to
     packaging with ice pack and styrofoam completed at MATRITECH for the
     purpose of keeping PRODUCTS in the appropriate condition under the
     transportation of PRODUCTS from MATRITECH's factory to KONICA's factory.

7.   QUALITY INSPECTION

7.1  It is the responsibility of MATRITECH to test and inspect, at its own
     expenses and in accordance with the methods and standards agreed upon by
     the parties hereto and attached hereto as Exhibit B ("INSPECTION
     STANDARDS"), all PRODUCTS before delivery thereof to KONICA in order to
     check and secure the conformity with such quality and characteristics of
     PRODUCTS as set forth in the product specification attached hereto as
     Exhibit C ("PRODUCT SPECIFICATION"). MATRITECH shall issue KONICA in
     advance certificate of analysis and certificate of conformance for PRODUCTS
     by facsimile and registered mail which have passed its own test and
     inspection as set forth above.

7.2  KONICA shall conduct, at its own expenses and in accordance with the
     INSPECTION STANDARDS, acceptance test and inspection of PRODUCTS in order
     to check and secure the conformity with such quality and characteristics of
     PRODUCTS as set forth in the PRODUCT SPECIFICATION, for which such quality
     certificate of MATRITECH as

<PAGE>

                                      -7-

     set forth in Section 7.1 above has been issued, before accepting such
     PRODUCTS. KONICA may reject the whole or any part of such PRODUCTS as not
     being in conformity with quality and characteristics of PRODUCTS as set
     forth in the PRODUCT SPECIFICATION. If the nature of non-conformance of the
     PRODUCT SPECIFICATION is such that the whole lot of PRODUCTS does not have
     to be rejected then KONICA will make a good faith effort to only reject the
     PRODUCTS as not being in conformity with the PRODUCT SPECIFICATION.

7.3  In case any PRODUCTS have been mutually agreed not to be in conformity with
     the PRODUCT SPECIFICATION as a result of test and inspection in accordance
     with the INSPECTION STANDARDS, MATRITECH shall deliver to KONICA the
     substitute PRODUCTS within thirty (30) days from the mutual agreement under
     the INSPECTION STANDARDS. All expenses relating to delivery of substitute
     PRODUCTS shall be borne by MATRITECH.

8.   PACKAGING, PACKING AND MARKING

     All packaging, packing and marking (including labeling and printing),
     package inserted instruction and such necessary description as required by
     relevant regulations, for the purpose of marketing and distribution of
     PRODUCTS in the TERRITORY and transportation of PRODUCTS from MATRITECH to
     KONICA, shall be made by MATRITECH in accordance with KONICA's
     instructions, at MATRITECH's expenses. MATRITECH shall accept reasonable
     use labeling for PRODUCTS to be sold in the TERRITORY in accordance with
     KONICA's instructions; provided, however, that regarding said labeling,
     each party hereto shall respect the domestic legal requirement of the other
     party.

9.   WARRANTY

9.1  MATRITECH warrants to KONICA that PRODUCTS to be sold hereunder shall
     conform to the PRODUCT SPECIFICATION and satisfy the INSPECTION STANDARDS
     for the period of shelf life of PRODUCTS. OTHER THAN ANY WARRANTIES
     SPECIFIED IN THIS SECTION 9 HEREOF, THERE ARE NO WARRANTIES OF ANY KIND,
     INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
     A PARTICULAR PURPOSE RELATING TO THE PRODUCTS. MATRITECH SHALL NOT BE

<PAGE>

                                      -8-

     LIABLE FOR ANY LOST PROFIT, LOSS OF GOODWILL OR OTHER ECONOMIC LOSS, OR FOR
     ANY COLLATERAL, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND
     WITH RESPECT TO A BREACH OF MATRITECH'S WARRANTIES UNDER THIS SECTION 9.

9.2  In case, after the mutual inspection as set forth in Section 7, any
     PRODUCTS sold to KONICA have not conformed to the PRODUCT SPECIFICATION
     within the period of shelf life of PRODUCTS by mutual agreement, MATRITECH
     shall, at its expenses and responsibility, deliver to KONICA the substitute
     PRODUCTS within thirty (30) days from the mutual agreement.

9.3  If original shelf life of PRODUCTS becomes equal to or more than [REDACTED]
     months, MATRITECH shall guarantee that the remaining shelf life of PRODUCTS
     shall be at least [REDACTED] months at the time when PRODUCTS have been
     handed over into the charge of the customs clear agent in Narita airport
     designated by KONICA. If it is proved definitely that original shelf life
     of PRODUCTS shall be more than [REDACTED] months, MATRITECH shall guarantee
     that the remaining shelf life of PRODUCTS shall be at least [REDACTED] of
     original shelf life thereof at the above mentioned time.

9.4  This Section 9 shall survive any termination or expiration of this
     Agreement.

10.  SALES PROMOTION AND ADVERTISING

10.1 KONICA agrees to exert its best efforts to obtain the largest possible
     sales volume of PRODUCTS in the TERRITORY and to win, maintain and promote
     the goodwill for PRODUCTS among customers.

10.2 KONICA will, at its responsibility in principle, maintain an adequate stock
     of PRODUCTS, actively undertake advertising, hold or participate in
     exhibitions and implement other means of sales promotion of PRODUCTS.

11.  REPORTING

     KONICA shall provide MATRITECH with annual sales report and provide
     MATRITECH quarterly with rolling sales forecast covered for one (1) year
     regarding PRODUCTS.

<PAGE>

                                      -9-

12.  CUSTOMER SERVICE

     KONICA shall perform necessary customer services for PRODUCTS in the
     TERRITORY at its responsibility. MATRITECH shall provide KONICA with
     reasonable and adequate marketing support, including but not limited to a
     copy of sales promotional brochures, catalogues, manuals and any other
     literature relating to PRODUCTS in English, and shall furnish KONICA with
     necessary information in writing as requested by KONICA for the purpose of
     correspondence of customer's claim.

13.  TRADEMARKS

13.1 The packages of PRODUCTS sold by MATRITECH hereunder shall bear the
     TRADEMARKS. The parties hereto acknowledge that the trademark "device and
     Matritech" and "UNMP" and the goodwill symbolized thereby shall be and
     remain the sole property of MATRITECH and the trademark "Konica" and
     [JAPANESE CHARACTERS] and any goodwill symbolized thereby shall be and
     remain the sole property of KONICA. The trademark "device and Matritech"
     shall be affixed to the packages of PRODUCTS more conspicuously than the
     trademark "Konica", which is more fully specified in the Exhibit A attached
     hereto.

13.2 Except as explicitly authorized by this Agreement, nothing herein contained
     shall be construed as the transfer or grant of a license from MATRITECH to
     KONICA or from KONICA to MATRITECH of any tradenames, trademarks, patents,
     designs, copyrights and/or any other industrial property rights of
     MATRITECH or KONICA, whether registered or not, used or embodied in or in
     connection with PRODUCTS.

14.  INABILITY OF SUPPLYING PRODUCTS

     In case that the supply and/or manufacture of PRODUCTS by MATRITECH will be
     impossible or suspended for whatever reasons for a period greater than
     sixty (60) consecutive days at any time during the term of this Agreement
     except for force majeure and after a reasonable period of cure, and that
     such inability situation shall not have been cured by MATRITECH within
     forty-five (45) days after such sixty (60) consecutive day period,
     MATRITECH shall license, sub-license or have licensed any patent and know
     how contained in or relating to PRODUCTS including the relevant patents of
     Massachusetts Institute of Technology (MIT) and the trademark "UNMP" to
     KONICA with the most favorable royalty and conditions, and also shall
     provide KONICA with materials including cell lines and other technologies
     as requested by KONICA for the

<PAGE>

                                      -10-

     purpose of manufacture of PRODUCTS by KONICA. This Section 14 shall survive
     any termination or expiration of this Agreement.

15.  KONICA'S IMPROVEMENTS

     During the term of this Agreement, KONICA shall, upon request by MATRITECH,
     grant to MATRITECH at the most favorable royalty and conditions, a sole,
     non-transferable, worldwide, without any right to sublicense to others,
     license to make, use and sell the PRODUCTS under any and all improvements
     to PRODUCTS developed by KONICA. Nothing herein contained shall be
     construed as a grant of a license from KONICA to MATRITECH with respect to
     any other products except for PRODUCTS, and KONICA shall be free to use
     such improvements to any products.

16.  PROCUREMENT OF PERMITS

16.1 KONICA shall use its best efforts in performing clinical trial and other
     testing of PRODUCTS required for KOSEISHO submission, KOSEISHO APPROVAL and
     acquirement of Social Insurance Medical Fee ("SIMF"), subject to
     MATRITECH's assistance pursuant to Section 16.2 below. The target time
     frame for submission to KOSEISHO by KONICA, procurement of KOSEISHO
     APPROVAL and acquirement of SIMF shall be as follows; provided that
     MATRITECH shall deliver to KONICA the third lot of PRODUCTS (Order No.:
     94-N008) not later than [REDACTED] and that all such PRODUCTS shall pass
     KONICA's inspection under the INSPECTION STANDARDS:

     (a)  Time to KOSEISHO submission: [REDACTED]

     (b)  Time to KOSEISHO APPROVAL: [REDACTED]

     (c)  Time to acquire SIMF: [REDACTED]

     Provided, that above target time frame may be extended on a day for day
     basis for every day when the delivery of PRODUCTS (Order No.: 94-N008) is
     delayed, and may be changed upon mutual consultation and agreement in good
     faith, subject to the problems related to product quality, clinical
     evaluation performance, uncontrollable factors by KONICA or others.

16.2 MATRITECH shall provide KONICA with reasonable and adequate technical
     assistance during the period of the clinical trial, submission to KOSEISHO
     and acquirement of SIMF conducted by KONICA, and shall furnish KONICA with
     necessary information as requested by KONICA for the purpose of procurement
     of any license or permits required

<PAGE>

                                      -11-

     in Japan and conforming with any relevant regulations, subject that such
     information shall have been already in MATRITECH's possession. MATRITECH
     shall furnish KONICA with such information relating to characteristics and
     safety of materials and methods and quality control of manufacture of
     PRODUCTS and other relevant information as may be required for procurement
     of such license or permits at its responsibility, whether or not such
     information shall be in MATRITECH's possession; provided, that if the
     furnishment of such information incurs significant expenses, the parties
     hereto shall negotiate in good faith and come to mutual agreement for the
     reimbursement of MATRITECH's reasonable expenses by KONICA.

16.3 MATRITECH shall provide US clinical trial data in summary form and testing
     data of PRODUCTS required for FDA submission in summary form to KONICA in
     support of KONICA's KOSEISHO submission and subsequent marketing efforts.

16.4 MATRITECH shall be responsible for procuring any license or permits
     required to manufacture and export PRODUCTS, or for otherwise complying
     with the local regulations in U.S. and shall obtain such license and
     permits, at its own expenses.

17.  SECRECY

     During the term of this Agreement and for three (3) years thereafter, each
     party hereto shall keep and cause to be kept confidential and may not
     disclose in any manner to any third party any information as marked
     "CONFIDENTIAL" acquired from the other party during the term of this
     Agreement in connection with or in the course of performance of this
     Agreement or SALES CONTRACT, including but not limited to the terms and
     conditions of this Agreement and SALES CONTRACT, price of PRODUCTS,
     marketing strategy and technical and sales data, and shall not use those
     informations for the purpose other than the performance required in this
     Agreement; except for the following information:

     (a)  which, at the time of disclosure by the other party, is in the public
          domain;

     (b)  which, after the time of disclosure by the other party, is published
          or otherwise becomes part of the public domain without any fault on
          the part of the receiving party;

<PAGE>

                                      -12-

     (c)  which can be established in the documented form that it was rightfully
          in the possession of the receiving party at the time of disclosure by
          the other party and was not acquired directly or indirectly from the
          other party;

     (d)  which is or becomes available to the receiving party or to the general
          public from any third party not having a confidential relationship
          with the other party;

     (e)  which is or becomes reasonably necessary to be disclosed to KONICA's
          sales representatives, dealers and customers for sales of PRODUCTS; or

     (f)  which is required by law to be disclosed.

18.  HOLD HARMLESS

18.1 During the term of this Agreement and thereafter, MATRITECH shall indemnify
     and hold KONICA harmless against any claim or demand by any third party for
     damages, losses or costs including attorney's fees directly caused by,
     including without limitation, accident, injury or hazard to person,
     property or human health, arising out of or resulting from such PRODUCTS as
     not being in conformity with the PRODUCT SPECIFICATION.

18.2 During the term of this Agreement and thereafter, KONICA shall indemnify
     and hold MATRITECH harmless against any claim or demand by KONICA's sales
     representatives, dealers or customers for damages, losses or costs arising
     out of or resulting from service of or advertising of PRODUCTS conducted by
     KONICA, excluding any product liability claim arising out of the PRODUCTS
     to be sold hereunder.

19.  TERM

     This Agreement shall become effective from the date of execution of this
     Agreement and shall remain in force until lapse of six (6) years from the
     submission of PRODUCTS to KOSEISHO or January 31, 2002 whichever comes
     latest, unless earlier terminated pursuant to Section 20 below. Thereafter,
     this Agreement shall be extended for further two (2) year periods, unless
     either party hereto gives the other party the termination notice at least
     six (6) months prior to the expiration of the original or any such extended
     period of this Agreement.

<PAGE>

                                      -13-
20.  EARLIER TERMINATION

20.1 Each party hereto shall, without prejudice to any other remedies available
     to such party, have the right to forthwith terminate this Agreement and/or
     SALES CONTRACT, in whole or in part, at any time by giving the other party
     a written notice:

     (a)  if the other party shall commit any breach or failure to observe or to
          perform any of the material provisions of this Agreement and/or SALES
          CONTRACT, and such breach or failure shall not have been cured within
          thirty (30) days after the date of a written notice of such breach or
          failure given by the non-defaulting party;

     (b)  if any proceeding under any bankruptcy, reorganization, arrangement or
          insolvency law or similar law for the relief of debtors shall be
          instituted by or against the other party whether or not resulting in
          adjudication;

     (c)  if a receiver, trustee or liquidator shall be appointed to take charge
          of all or portion of the other party's assets under any provisions of
          bankruptcy or insolvency law or similar law for the relief of debtors;
          or

     (d)  if the other party shall suspend or cease or threaten to suspend or
          cease its ordinary business operations or any substantial part
          thereof.

20.2 The non-defaulting party in Section 20.1 (a) above shall have the right to
     suspend its performance or fulfillment of any obligation except for the
     obligation to pay monies owed which are not in dispute at the time of the
     default as set forth in this Agreement and SALES CONTRACT without liability
     for indemnification to the defaulting party, for the period from the date
     of the written notice of such breach or failure set forth in Section 20.1
     (a) above to the date of the adequate cure of such breach or failure by
     such defaulting party, or to the date of termination of this Agreement
     and/or cancellation of SALES CONTRACT, as the case may be.

20.3 In case the parties hereto mutually determine that the KOSEISHO APPROVAL
     can not be procured as to PRODUCTS notwithstanding best efforts of KONICA
     under MATRITECH's assistance pursuant to Section 16.2, this Agreement shall
     be terminated without incurring any liability for indemnification on each
     party to the other party due to such termination.

21.  BREACH OF CONTRACT

     In the case of breach by either party of any material term, condition or
     warranty of this Agreement and/or SALES CONTRACT, such breaching party
     shall be liable to the other

<PAGE>

                                      -14-

     party for all losses and damages directly caused by its breach of contract,
     upon request by the other party after the period of cure of such breach as
     set forth in Section 20.1 (a), without prejudice to any other remedies to
     the other party provided herein, including but not limited to the right of
     termination hereof pursuant to Section 20.1. This Section 21 shall survive
     any termination or expiration of this Agreement.

22.  NOTICE

     All notices specifically required by this Agreement or by SALES CONTRACT
     under this Agreement shall be in writing in English and shall be sent by
     registered airmail, or by facsimile subject to confirmation by registered
     mail, to the following address, unless otherwise instructed by written
     notice of the other party:

If to MATRITECH:  Mr. David L. Corbet
                  President and Chief Operating Officer

                  MATRITECH INC.
                  763 Concord Avenue, Cambridge,
                  MA 02138, U.S.A.
                  Facsimile: 617-661-8522

If to KONICA:     Mr. Shigeru Suzuki
                  Director and Division Executive Officer
                  Medical Products Marketing Division

                  KONICA CORPORATION 262, Nishi-shinjuku 1-chome,
                  Shinjuku-ku, Tokyo 163-05, Japan Facsimile:
                  81-425-87-3335

     Any notices shall be deemed to have been duly given and made, unless
     otherwise specifically provided in this Agreement, i) when such registered
     airmail shall have been deposited in the mail, postage prepaid, or ii) when
     such facsimile shall have been

<PAGE>

                                      -15-

     received by the other party, subject to receipt by such other party of
     confirmation thereof by registered mail, postage prepaid, within fifteen
     (15) days.

23.  EFFECT OF TERMINATION

     No expiration or no earlier termination (collectively "termination") of
     this Agreement shall release each party from any liability which at such
     time has already accrued to the other party, nor shall in any way affect
     the survival of any right, duty or obligation of each party which is
     contemplated to be performed as of the date of or after such termination.

24.  FORCE MAJEURE

     Neither party hereto shall be responsible for failure or delay in the
     performance of its obligations under this Agreement and/or any SALES
     CONTRACT due to cause(s) beyond its control, including but not limited to
     acts of God, strikes, labor troubles, inevitable accidents, shortage or
     delay of carriers, shortage of raw materials, labour, power or other
     utility services, war, riots, civil commotion, embargoes, blockades,
     prohibition of exportation, governmental direction, intervention of
     government agencies or legal restrictions. In such cases, performance by
     such party of this Agreement and/or any SALES CONTRACT shall be suspended
     without liability for indemnification to the extent of affected performance
     and for the period of delay reasonably attributable to such causes,
     including but not limited to recovery time.

25.  PATENT INDEMNIFICATION

25.1 During the term of this Agreement and thereafter, MATRITECH shall indemnify
     and hold KONICA harmless against any claim of infringement of any patent,
     copyright, design or other intellectual property rights with respect to the
     PRODUCTS purchased by KONICA hereunder, except as provided in Section 25.3
     below. In the event a third party at any time brings suit against KONICA
     anywhere in the TERRITORY claiming infringement of its patent rights or
     unauthorized use or misappropriation of its technology, based on a claim
     arising out of the use or sale of the PRODUCTS, MATRITECH shall have sole
     and exclusive right to take all appropriate legal action with respect
     thereto. KONICA shall, after receipt of notification of a third party claim
     or notice of commencement of any action, suit or proceeding of the type
     described in the preceding sentence, notify MATRITECH of such claim or the
     commencement of said

<PAGE>

                                      -16-

     action, suit or proceeding, enclosing a copy of all papers served. KONICA
     shall not settle, compromise or agree to the dismissal of any such suit
     involving the rights of MATRITECH without obtaining the prior written
     consent of MATRITECH.

25.2 KONICA shall promptly report in writing to MATRITECH during the term of
     this Agreement any i) known infringement or suspected infringement by a
     third party in the TERRITORY, or ii) unauthorized use or misappropriation
     by a third party in the TERRITORY, of any patent and/or trademark of
     MATRITECH relating to or covering the PRODUCTS, of which it becomes aware,
     and shall provide MATRITECH with all available evidence supporting said
     infringement, suspected infringement or unauthorized use or
     misappropriation. MATRITECH shall have the sole and exclusive right and
     obligation to initiate an infringement or other appropriate suit anywhere
     in the TERRITORY against any third party who at any time has infringed, or
     is suspected of infringing, any patent and/or trademark of MATRITECH
     pertaining to the PRODUCTS.

25.3 During the term of this Agreement and thereafter, KONICA shall indemnify
     and hold MATRITECH harmless against any claim of infringement of any
     patent, copyright, design or other intellectual property rights with
     respect to; i) the trademarks , "Konica" and [JAPANESE CHARACTERS], and ii)
     the improvements made by MATRITECH under the instruction of KONICA to the
     PRODUCTS purchased by KONICA hereunder.

26.  RECALL AND WITHDRAWAL

     The parties hereto acknowledge that recall/withdrawal of PRODUCTS
     distributed by KONICA to its customers may be made in case i) such recall
     is ordered or requested by a competent governmental authority or ii) such
     withdrawal is mutually agreed upon by the parties hereto ("PRODUCTS
     RECALL/WITHDRAWAL"). KONICA agrees to take any action as both parties deem
     necessary to facilitate and implement the PRODUCTS RECALL/WITHDRAWAL.
     MATRITECH will bear the direct costs and expenses incurred in connection
     with the implementation of the PRODUCTS RECALL/WITHDRAWAL if and to the
     extent such PRODUCTS RECALL /WITHDRAWAL is taken place due to the PRODUCTS
     not conforming to the PRODUCT SPECIFICATION; provided, however, that such
     non-conformance is not due to improper transport, storage or use of the
     PRODUCTS, and KONICA will bear such

<PAGE>

                                      -17-

     direct costs and expenses if and to the extent such PRODUCTS
     RECALL/WITHDRAWAL is taken place due to negligence of KONICA.

27.  NON-WAIVER

     No failure to exercise or delay in exercising any right under this
     Agreement and/or any SALES CONTRACT shall operate as a waiver thereof, nor
     shall any single or partial exercise of any of such rights thereunder
     preclude any other or further exercise of such rights or the exercise of
     any other rights.

28.  NON-ASSIGNABILITY

     Neither party hereto may, in whole or in part, assign, transfer, pledge,
     encumber or otherwise dispose of this Agreement or any SALES CONTRACT or
     any such rights or obligations on its part as are created thereunder to any
     third party, without the prior written consent of the other party;
     provided, however, that MATRITECH may assign its rights and obligations
     under this Agreement in connection with the sale of its entire business
     relating to the PRODUCTS, if and on condition that, KONICA confirms in
     writing prior to the assignment that the assignee of such MATRITECH's
     rights and obligations assumes all contractual obligations of MATRITECH
     hereunder without any substantial changes thereon, and in such case, KONICA
     will not withhold its consent for such assignment.

29.  PARTIAL INVALIDITY

     The parties hereto agree that invalidity or unenforceability of any of the
     provisions, in part or in whole, of this Agreement or any SALES CONTRACT
     shall not in any way affect the validity or enforceability of any other
     parts or provisions thereof except those which are an integral part of or
     are otherwise clearly inseparable from such invalid or unenforceable part
     or provision.

30.  HEADINGS

     The headings to Sections or elsewhere in this Agreement are only for
     convenience of reference without forming a part of this Agreement and shall
     not in any way affect the interpretation thereof.

31.  TRADE TERMS AND APPLICABLE LAW

31.1 The trade terms used in this Agreement and any SALES CONTRACT shall be
     interpreted in accordance with the provisions of the "Incoterms" (the
     International Rules

<PAGE>

                                      -18-

     for the Interpretation of Trade Terms established by the International
     Chamber of Commerce), as amended and supplemented from time to time.

31.2 This Agreement and any SALES CONTRACT shall be governed by and construed in
     accordance with the substantive laws of the State of New York without
     reference to other laws.

32.  ARBITRATION

     All disputes, controversies or differences which may arise, during the term
     of this Agreement or thereafter, between the parties hereto, out of or in
     connection with this Agreement or any SALES CONTRACT, or for the breach
     thereof, shall be finally settled by arbitration pursuant to the
     Japan-American Trade Arbitration Agreement of September 16, 1952 ("JATAA"),
     by which each party hereto is bound. The place of arbitration shall be New
     York, U.S.A., if the defendant party is MATRITECH, or Tokyo, Japan, if the
     defendant party is KONICA; provided, however, that nothing in this Section
     32 shall be construed to preclude either party from seeking provisional
     remedies, including, but not limited to, temporary restraining orders and
     preliminary injunctions, from any court of competent jurisdiction, in order
     to protect its rights pending arbitration, but such preliminary relief
     shall not be sought as a means of avoiding arbitration. The parties hereto
     shall have the right of prehearing discovery, including, without
     limitation; i) exchange of witness lists, ii) exchange of documentary
     evidence and reasonably related documents, iii) written interrogatories,
     and iv) subject to the reasonable discretion of the arbitrators and upon
     good cause shown depositions under oath or any witnesses who are to be
     called to testify at the arbitration hearing. As soon as the discovery is
     concluded, the arbitrators shall hold one or more hearings on as expedited
     a schedule as proves practicable in accordance with the aforesaid JATAA
     rules. The award of the arbitration shall be final and binding upon both
     parties hereto.

33.  ENTIRE AGREEMENT AND MODIFICATION

33.1 This Agreement is the final expression of the entire and only agreement of
     both parties with respect to the subject matter covered in this Agreement
     and supersedes all previous oral or written agreements, negotiations,
     commitments and representations with respect thereto.

<PAGE>

                                      -19-

33.2 This Agreement cannot be changed, modified or amended in any manner except
     by mutual agreement in writing signed by duly authorized representatives of
     both parties hereto.

33.3 This Agreement has been drafted in English but may be translated into
     Japanese; provided, however, that the English language version shall be
     controlling.

<PAGE>

                                      -20-

IN WITNESS WHEREOF, both parties hereto have caused this Agreement to be
executed by their duly authorized representatives as of the date first above
written.

MATRITECH INC.                              KONICA CORPORATION

/s/ David L. Corbet                         /s/ Shigeru Suzuki
-------------------------------             ------------------------------------
By: David L. Corbet                         By: Shigeru Suzuki
Title: President and Chief                  Title:   Director and Division
       Operating Officer                             Executive Officer
                                                     Medical Products Marketing
                                                     Division

Date: December 1, 1994                      Date:  November 17, 1994
      -------------------------                    ----------------------------

<PAGE>

                                    EXHIBIT A
                                 - TRADEMARKS -
          [JAPANESE CHARACTERS] Matritech UNMP 22 [JAPANESE CHARACTERS]
                       (Konica Matritech UNMP22 test kit)

<PAGE>

1.   PRODUCTS NAME

          [JAPANESE CHARACTERS] Matritech UNMP22 [JAPANESE CHARACTERS]

2.   MATRITECH'S TRADEMARK

                                    MATRITECH

3.   KONICA'S TRADEMARK

     KONICA

<PAGE>

                                    EXHIBIT B
                            - INSPECTION STANDARDS -
          [JAPANESE CHARACTERS] Matritech UNMP22 [JAPANESE CHARACTERS]
                       (Konica Matritech UNMP22 test kit)

<PAGE>

1.   TEST KIT INSPECTION

1-1 PROPER LABELING

     Reagent bottles, foils, cartons and shippers shall be 100% inspected for
     content, position, and quality of the information printed during
     manufacturing. The 100% inspection may be changed by mutual agreement of
     both Matritech and Konica.

     Each lot is sampled and tested for proper labeling of reagent bottles and
     foils of the kit components.

1-2 LOT NUMBERS

     The items specified will have a lot number and the lot number shall be
     clearly printed in the specified position.

1-3 EXPIRATION DATES

     The items specified will have an expiration date and the expiration date
     shall be printed in the specified position.

1-4 SOIL DAMAGE

     Soil damage shall not affect the marketability of the products.

1-5 WATER DAMAGE

     Water damage shall not affect the marketability of the products.

1-6 PHYSICAL DAMAGE

     a) Shipper;     Damage shall not affect the marketability of the products.
     b) Carton;      Damage shall not affect the marketability of the products.
     c) Bottles;     Damage shall not affect the marketability of the products.
                     Each bottles shall be properly sealed.

     Each lot is sampled and tested for integrity of the sealing of the cap.

1-7 TEMPERATURE INTEGRITY OF SHIPMENT

     When packing Test Kit for shipment, a temperature recorder is packed inside
     of a randomly selected crate so that temperature changes during shipment
     may be monitored.

     However, said temperature recorder can be neglected or substituted to other
     temperature warning method under the mutual agreement.

<PAGE>

1-8 SHIPMENT NOTIFICATION

     A Shipment Notification shall be sent to Konica such that it is received
     prior to receiving the shipment. This contains a list of lot numbers,
     quantities, purchase orders represented by the shipment, and a statement
     that the products conform to the specification.

1-9 CERTIFICATE OF ANALYSIS

     For each lot number, a certificate of analysis shall be mailed to QA
     Operations at Konica.

2.   PERFORMANCE TESTING

2-1 TEST KIT PERFORMANCE

     Test Kit Performance is characterized by sensitivity, specificity,
     reproducibility and stability.

     Test Kit Performance Testing is done on each lot to determine product
     performance characteristics. The protocol is specified in the SUPPLEMENTAL
     RELEASE PROCEDURES.

     The level of absorbance or value is determined with mean level of described
     number of assay in the SUPPLEMENTAL RELEASE PROCEDURES.

2-1-1 SENSITIVITY

     Sensitivity is defined as absorbance at wavelength of 492nm per unit in
     zero fixed linear regression of Calibrators, and that absorbance per unit
     shall be within range of allowance.

     In addition, absorbance in Calibrator No.l shall be below the definite
     level, and coefficient correlation of linear regression shall be within
     allowance.

     Mean absorbance of Calibrator No.l. at 492nm is less than the acceptance
     limit listed in SUPPLEMENTAL RELEASE PROCEDURES.

     Slope in zero fixed linear regression using mean absorbance of Calibrator
     No. 1 to No.7. is within the acceptance limit listed in SUPPLEMENTAL
     RELEASE PROCEDURES.

2-1-2 SPECIFICITY

     Specificity is defined as +/-bias % having against assigned controls. Each
     level of three Controls shall be within +/-bias % of allowance.

     Moreover, in order to maintain the absorbance value, both sites of
     Matritech and Konica shall have sufficient number of "mastercontrol" in
     frozen below -80 (degree)C. These master control shall be assayed at the
     same time and shall be within +/-bias % of allowance.

<PAGE>

     Each value of Control I to III is within the acceptance listed in
     SUPPLEMENTAL RELEASE PROCEDURES.

     The value of master control is within the acceptance limit listed in
     SUPPLEMENTAL RELEASE PROCEDURES.

2-1-3 REPRODUCIBILITY

     Reproducibility is defined as Coefficient of Variation (C.V.%) of values in
     three Controls.

     Each C.V.% of Control I to III is within the acceptance listed in
     SUPPLEMENTAL RELEASE PROCEDURES.

2-1-4 DISPOSITION OF RETESTING

     Results falling outside of specification may indicate an unacceptable lot.

     Three possible actions may be taken ;

     a)   Reject the lot based in the initial test results if re-testing does
          not appear to be promising.

     b)   Retest the lot and combine all the results together to compare to
          specification.

          Release if acceptable.

     c)   Determine through investigation that the initial performance results
          were incorrect due to a specific testing error for which corrective
          action has been taken. Initial data may be discarded and new data
          collected.

2-2 CALIBRATOR VALUE CHECK

     The assigned value of each Calibrator is checked on each lot to determine
     product performance characteristics. The protocol is specified in the
     SUPPLEMENTAL RELEASE PROCEDURES.

2-2-1 CALIBRATOR VALUE VERIFICATION

     Absorbance of Calibrator No.l and No.7 is within the allowance listed in
     SUPPLEMENTAL RELEASE PROCEDURES.

     The assigned values of Calibrator from No.l to No.7 is within the allowance
     listed in SUPPLEMENTAL RELEASE PROCEDURES.

     The correlation coefficient in zero fixed linear regression using mean
     absorbance of Calibrator from No.l to No.7 is more than the allowance shown
     in SUPPLEMENTAL RELEASE PROCEDURES.

<PAGE>

2-2-2 DISPOSITION OF RETESTING

     Results falling outside of specification may indicate an unacceptable lot.

     Two possible actions may be taken;

     a)   Reject the lot based in the initial test results if re-testing does
          not appear to be promising.

     b)   Determine through investigation that the initial performance results
          were incorrect due to a specific testing error for which corrective
          action has been taken. Initial data may be discarded and new data
          collected.

2-3 CONTROL VALUE CHECK

     The assigned value of each Control is checked on each lot to determine
     product performance characteristics. The protocol is specified in the
     SUPPLEMENTAL RELEASE PROCEDURES.

2-3-1 CONTROL VALUE VERIFICATION

     The assigned value in each Control from I to III is within the allowance
     listed in SUPPLEMENTAL RELEASE PROCEDURES.

     Each result values of Control from I to III is within each control range
     described in its label on the bottle.

2-3-2 DISPOSITION OF RETESTING

     Results falling outside of specification may indicate an unacceptable lot.

     Two possible actions may be taken ;

     a)   Reject the lot based in the initial test results if re-testing does
          not appear to be promising.

     b)   Determine through investigation that the initial performance results
          were incorrect due to a specific testing error for which corrective
          action has been taken. Initial data may be discarded and new data
          collected.

3. VERIFICATION OF SHELF LIFE

3-1 REAL TIME SHELF LIFE VERIFICATION

     Verification of Shelf Life shall be determined by the difference between
     the values obtained from the Test Kits of a lot immediately after
     manufacturing and the values obtained from the Test Kits of the same lot
     after storage at 2(degree)C to 10(degree)C in unopened bottle for a period
     not less than the expiry age for the reagent.

<PAGE>

3-2 STRESSED LIFE VERIFICATION

     Only when changing either a formula or a process, or both, a test of
     putting a small trial sample in accelerated stress conditions such as 7
     days at 37(degree)C is performed. The results of the test along with the
     data of unstressed samples are to be submitted when released. No judgement
     of the release and acceptance shall be made with performance of the
     stressed samples.

4. OTHERS

4-1 PRODUCT SAMPLE

     Both Matritech and Konica keeps significant amount of production sample of
     the Product in each lots, in order to provide the soonest measure for
     customer complaints.

     Such production sample is kept for at least 3 months more than its original
     expiration.

4-2 RECEIVING INSPECTION

     For each shipment from Matritech to Konica, Konica shall perform the
     receiving inspection referred to the EXHIBIT B -INSPECTION STANDARDS.

     However, such receiving inspection can be neglected under the decision of
     Konica.

<PAGE>

                                    EXHIBIT C
                            - PRODUCT SPECIFICATION -
          [JAPANESE CHARACTERS] Matritech UNMP22 [JAPANESE CHARACTERS]
                       (Konica Matritech UNMP22 test kit)

<PAGE>

1.   DEFINITION

     This Product Specification is defined in order to maintain the quality of
     [JAPANESE CHARACTERS] Matritech UNMP22 [JAPANESE CHARACTERS] (Konica
     Matritech UNMP22 test kit) which consists of a microtiter plate based
     enzyme immunoassay and quantifies NMP22 in urine of patients for the
     diagnosis, monitoring or prognosis of urinary tract disorders and/or
     diseases, and further includes 96 determinations per test kit, that
     Matritech Inc. (hereafter Matritech) manufactures and Konica Corporation
     (hereafter Konica) distributes within the Territory.

     Terminology:

             Product;              Test Kit, Carton and Shipper
             Test Kit;             Konica Matritech UNMP22 Test Kit
             Carton;               Box that contains components.
             Shipper;              Box that contains cartons.

2.   SCOPE

     This Product Specification is effective for the performance, standard and
     packaging of [JAPANESE CHARACTERS] Matritech UNMP22 [JAPANESE CHARACTERS]
     (Konica Matritech UNMP22 test kit) according to the SUPPLY AND PURCHASE
     AGREEMENT executed November 17, 1994 between Matritech and Konica.

3.   KIT COMPONENTS

     Kit Components would be referred to Attachment 1.

4.   LOT NUMBER AND EXPIRATION DATE

4-1 DEFINITION OF LOT -

     Lot number of the kit is defined to as kits packaged in the same day by the
     same batch in all components.

     Lot number of the reagent is defined to the reagents manufactured and
     assigned in the same day.

4-2 LOT NUMBER ASSIGNMENT-

     Lot number is assigned in 6 digits. Each digit is named as follows;

example
       1  1  4  0  0  1
       |  |  |  |  |  |
       |  |  |   ------------------------ manufacturing serial number (3 digits)
       |  |  ---------------------------- the last digit of the year
       |--|------------------------------ month

<PAGE>

                             Table 1 : code of month

                    -----------------------------------------
                           month                code
                    -----------------------------------------
                          January                01
                    -----------------------------------------
                          February               02
                    -----------------------------------------
                           March                 03
                    -----------------------------------------
                           April                 04
                    -----------------------------------------
                            May                  05
                    -----------------------------------------
                            June                 06
                    -----------------------------------------
                            July                 07
                    -----------------------------------------
                           August                08
                    -----------------------------------------
                         September               09
                    -----------------------------------------
                          October                10
                    -----------------------------------------
                          November               11
                    -----------------------------------------
                          December               12
                    -----------------------------------------

4-3   EXPIRATION DATE -

      Expiration date is defined as the date after X months from the next month
      of the manufacturing.

5.    SPECIFICATION

5-1   PRODUCT APPEARANCE -

5-1-1 LABELING

      For each components of the kit, labeling is specified in Attachment 2.

      Labeling and its printing must be proper and visibly clear.

5-1-2 PACKAGE

      The carton of the Product is specified as follows.

                 Dimension          : 219.1mm(W) x 158.8mm(L) x 89mm(H)
                 Material           : card board -150E flute

      The packing of the components of the Products in the carton are specified
      in Attachment 3.

      The printing to the carton is specified in Attachment 2.

      Carton printing and components layout must be proper and visibly clear.

      The shipper of the carton is specified as follows.

<PAGE>

                 Dimension          : 225mm(W) x 321mm(L) x 200mm(H)
                 Material           : corrugated box
                 Contents           : 6 cartons

      The packing of the cartons to the shipper is specified in Attachment 3.

      The printing to the shipper is specified in Attachment 2.

      The printing on the shipper and cartons layout must be proper and visibly
      clear.

      The format of the package inserted instruction is specified in
      Attachment 2.

5-1-3 APPEARANCE OF MATERIALS

      There shall be no significant aesthetic defects or degradation found in
      each reagent material of the components.

      The appearance of each components is specified in Attachment 1.

5-1-4 OTHERS

      There shall be no significant aesthetic defects to the Products.

5-2   PROTOCOL -

5-2-1 WAVELENGTH OF ABSORBANCE MEASUREMENT

                                     492 nm

5-2-2 OPERATION TIME AND TEMPERATURE

 Specimen, calibrator and control                      ; 200uL/well
  - incubate.......... 2 hours +/- 5 min. at 18(degree)C to 25(degree)C.
  - wash
 Add DIG~Anti-UNMP22                                   ; 200uL/well
  - incubate.......... 1 hours +/- 5 min. at 18(degree)C to 25(degree)C.
  - wash
 Add SAD-HRP                                           ; 200uL/well
  - incubate.......... 0.5 hours +/- 5 min. at 18(degree)C to 25(degree)C.
  - wash
 Add OPD solution                                      ; 200uL/well
  - incubate.......... 0.5 hours +/- 2 min. at 18(degree)C to 25(degree)C.
 Add 2M H2S04 to stop reaction                         ; 50uL/well
  - wait ............. 10 minutes.
  - read absorbance .......... no later than 30 minutes after addition of acid.
<PAGE>

5-3  PERFORMANCE -

5-3-1 TEST KIT PERFORMANCE

A.   Sensitivity (Slope of Standard Curve)

     Slope in zero fixed linear regression using absorbance of Calibrator No.l
     to No.7 ;

                                   [REDACTED]

B.   Specificity

     When any sample with known concentration are measured, the values obtained
     are within the limits listed in Table 2.

                     Table 2 : sample levels and allowances

    ----------------------------------------------------------------------------
      level              true value (U/mL)                 Allowance
    ----------------------------------------------------------------------------
       low                  [REDACTED]                     [REDACTED]
    ----------------------------------------------------------------------------
     middle                 [REDACTED]                     [REDACTED]
    ----------------------------------------------------------------------------
      high                  [REDACTED]                     [REDACTED]
    ----------------------------------------------------------------------------

C.   Reproducibility

     inter-assay C.V.             [REDACTED]           (across the entire assay)
     intra-assay C. V.            [REDACTED]

D.   Assay Range

     The assay range of this method is ;

                                   [REDACTED]

E.   The Low End Sensitivity

     The low end sensitivity of the assay        [REDACTED]

F.   Recovery Rates

     The recovery rates of added antigen          [REDACTED]

G.   Dilution Linearity Rates

<PAGE>

      The dilution linearity rates of urine samples           [REDACTED]

5-3-2 REQUIREMENT FOR CALIBRATOR

      Each levels of Calibrators must present the specified characteristics in
      Attachment 4.

      The correlation coefficient in zero fixed linear regression using mean
      absorbance of the Calibrator from No.l to No.7 is more than [REDACTED]

5-3-3 REQUIREMENT FOR CONTROL

      Each levels of Controls must present the specified characteristics in
      Attachment 5.

6.    OTHERS

6-1   DOCUMENTATION

      For each released lot, a Certificate of Analysis must be prepared from
      Matritech to Konica.

6-2   PRESENCE OF THE PROBLEM

      If there arouse problem to the quality of the Product, Matritech and
      Konica shall negotiate in good faith and do their best efforts to the
      solutions.
<PAGE>

ATTACHMENT 1. KIT COMPONENTS OF UNMP22

A.   Test Kit Components

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------
   No.                        Name                        form & Volume                  package
--------------------------------------------------------------------------------------------------------------
<S>        <C>                                           <C>                 <C>
   #la     3 [JAPANESE CHARACTERS] - 1 [JAPANESE           lyophilized       5mL flint glass bottle x3 with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No. l Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #lb     3 [JAPANESE CHARACTERS] - 2 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.2 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #lc     3 [JAPANESE CHARACTERS] - 3 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.3 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #ld     3 [JAPANESE CHARACTERS] - 4 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.4 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #le     3 [JAPANESE CHARACTERS] - 5 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.5 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #1f     3 [JAPANESE CHARACTERS] - 6 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.6 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #l g    3 [JAPANESE CHARACTERS] - 7 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 No.7 Unit/mL Calibrator
--------------------------------------------------------------------------------------------------------------
   #2a     4 [JAPANESE CHARACTERS] - 1 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 Control Level 1
--------------------------------------------------------------------------------------------------------------
   #2b     4 [JAPANESE CHARACTERS] - 2 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 Control Level 2
--------------------------------------------------------------------------------------------------------------
   #2c     4 [JAPANESE CHARACTERS] - 3 [JAPANESE           lyophilized       5mL flint glass bottle with
           CHARACTERS]                                                       split nosed stopper

           UNMP22 Control Level 3
--------------------------------------------------------------------------------------------------------------
    #3     8 [JAPANESE CHARACTERS] 96 [JAPANESE              1 plate         foiled in zip-lock with
           CHARACTERS]                                     8wells x 12       desiccant

           Coated Plate (96 determination)
--------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<S>        <C>                                           <C>                 <C>
--------------------------------------------------------------------------------------------------------------
    #4     1 [JAPANESE CHARACTERS]                        20mL solution      30mL HDPE bottle
                                                           clear amber
            DIG~Anti-UNMP22
--------------------------------------------------------------------------------------------------------------
    #5     2 [JAPANESE CHARACTERS]                        20mL solution      30mL HDPE bottle
                                                           clear amber
           HRP~SAD
--------------------------------------------------------------------------------------------------------------
    #6     OPD Development Buffer                         40mL solution      60mL HDPE amber bottle
                                                              clear
--------------------------------------------------------------------------------------------------------------
    #7     OPD Tablets                                      4 tablets        individual foil in plastic bag
--------------------------------------------------------------------------------------------------------------
    #8     Wash Solution 100 x Concentrate                30mL solution      30mL HDPE bottle
                                                              clear
--------------------------------------------------------------------------------------------------------------
    #9     Package Inserted Instruction                     1 booklet        folded paper
--------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

ATTACHMENT 3. COMPONENTS LAYOUT

A. Carton box and kit components

                    [graphic: Carton box and kit components]

<PAGE>

B. Carton Box Layout in Shipper Box

              [graphic: Carton Box Layout in Shipper Box top view]

             [graphic: Carton Box Layout in Shipper Box side view]

<PAGE>

CONFIDENTIAL TREATMENT

ATTACHMENT 4. REQUIREMENTS OF CALIBRATORS

   A. Assigned Value and Optical Density

--------------------------------------------------------------------------------
   Calibrator           (Assigned Value (U/mL)                  Absorbance
--------------------------------------------------------------------------------
      No.l                    [REDACTED]                        [REDACTED]
--------------------------------------------------------------------------------
      No.2                    [REDACTED]
--------------------------------------------------------------------------------
      No.3                    [REDACTED]
--------------------------------------------------------------------------------
      No.4                    [REDACTED]
--------------------------------------------------------------------------------
      No.5                    [REDACTED]
--------------------------------------------------------------------------------
      No.6                    [REDACTED]
--------------------------------------------------------------------------------
      No.7                    [REDACTED]                        [REDACTED]
--------------------------------------------------------------------------------

          note: Absorbance must increase in order of calibrator number.

<PAGE>

CONFIDENTIAL TREATMENT

ATTACHMENT 5. REQUIREMENTS OF CONTROLS

A. Assigned Value

-------------------------------------------------------------------------------
      Control                            Assigned Value (U/mL)
-------------------------------------------------------------------------------
         I                                     [REDACTED]
-------------------------------------------------------------------------------
        II                                     [REDACTED]
-------------------------------------------------------------------------------
        III                                    [REDACTED]
-------------------------------------------------------------------------------

B. Assigned Value and Control Range

--------------------------------------------------------------------------------
                          Values of Control Range (U/mL)
   Control     -----------------------------------------------------------------
               Minimum                                        maximum
--------------------------------------------------------------------------------
      I        (Assigned Value x [REDACTED]         (Assigned Value x [REDACTED]
--------------------------------------------------------------------------------
     II        (Assigned Value x [REDACTED]         (Assigned Value x [REDACTED]
--------------------------------------------------------------------------------
     III       (Assigned Value x [REDACTED]         (Assigned Value x [REDACTED]
--------------------------------------------------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]